Ambrx Appoints Gary Yeung as Main Fiscal Officer and Main Functioning Officer
3 min readSAN DIEGO, Jan. 7, 2021 /PRNewswire/ — Ambrx Inc. today declared the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Running Officer. Mr. Yeung provides considerable leadership working experience in raising money, setting up biotech businesses, and foremost businesses to develop novel therapeutics.
“Ambrx is at a important inflection place to advance our pipeline of Engineered Precision Biologics following our recent $200M private financing round. Gary’s powerful track file of increasing money and building groups that aid the advancement of breakthrough medications is timely,” said Dr. Feng Tian, Chairman, President and CEO. “Gary’s experience and leadership experience in finance, drug progress, system, portfolio administration, and operations uniquely situation him to deliver significant affect to our coming growth phases.”
“I am passionate about performing with providers that can alter patients’ lives. Dr. Tian and his staff have been the pioneers and innovators of the expanded genetic code technologies employing web page-precise incorporation of artificial amino acids into proteins to build drug candidates that are on the cusp of demonstrating the breakthrough nature of its system. In certain, I am energized about ARX788’s recent Quick Monitor Designation by the Food and drug administration and its opportunity to be the greatest-in-class, following-generation, anti-HER2 ADC primarily based on my experience of establishing and commercializing HER2 items,” stated Mr. Yeung. “I glance forward to partnering with the management staff and the board to develop the corporation and provide novel Engineered Precision Biologics to sufferers.”
Mr. Yeung joins Ambrx from Erasca, the place he served as CFO & COO aiding finance the business and advance numerous compounds into clinical trials. Prior to Erasca, Mr. Yeung helped establish two biotech companies, Guardant Wellbeing and Annexon Biosciences. At Guardant, he was vice president of the early most cancers detection business and a member of the leadership workforce. At Annexon, Mr. Yeung served as vice president of business enterprise and progress functions. He also devoted 12 several years at Genentech, creating organizations to develop and start modern therapies. He oversaw the portfolio and venture management functions that produced 42 INDs and made a lot of Food and drug administration-permitted treatment plans, such as Tecentriq and Venclexta. He also held management roles in finance and industrial operations to guidance the start and growth of the Immunology and BioOncology franchises. Previously in his occupation, Mr. Yeung was a marketing consultant with McKinsey and an operational leader with GE. He retains a B.S. in chemical engineering from the University of California, Berkeley, and an MBA from UCLA. He is a Chartered Economical Analyst (CFA).
About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical organization utilizing an expanded genetic code to produce Engineered Precision Biologics, this incorporates next era antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as novel cytokines to modulate the immune procedure and prolonged-performing therapeutic peptides for metabolic and cardiovascular disorder, all intended to have improved pharmacologic qualities and novel organic activity. Leveraging the Ambrx proprietary technological innovation platforms, Ambrx has collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, with drug products and solutions produced making use of Ambrx technological innovation in diverse phases of scientific trials. Ambrx is advancing a robust portfolio of scientific and preclinical systems optimized for efficacy, security and simplicity of use in various therapeutic places. For additional information and facts, pay a visit to www.ambrx.com.
Make contact with:
Amy Conrad
858-366-3243
[email protected]
Resource Ambrx Inc.